Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

    *This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
    May 10, 2017

    Understanding Today’s CAR-T Cell Therapy Manufacturing Challenges

    CAR-T cell therapy presents numerous challenges for cell therapy developers who are looking to move towards commercialization. The move from development to commercial ...

    Read More
    December 9, 2015

    NK Cells--Why Not?

    The following post was originally published in the November 2015 edition of The Vector, the online newsletter for the American Society of Gene and Cell Therapy. Chimeric ...

    Read More
    November 3, 2015

    Scoring the Goal—10 Questions to Ask your External Manufacturing Partner

    If you’re a striker (playing forward position) on a soccer team, you know that your primary role is to score a goal. But what makes you confident in your ability to ...

    Read More
    August 4, 2015

    Bridging the Gap with Chimeric Antigen Receptors

    Cell therapies armed with crafted weaponry in the form of CARs (Chimeric antigen receptors) and engineered TCRs (T cell receptors) have taken immuno-oncology to a new ...

    Read More
    All Posts

    Subscribe to Our Email Distribution List
    © 2025 Minaris Regenerative Medicine   |  Privacy Policy   |  Imprint